Cardiometabolic Innovations Using GLP-1 Receptor Therapy

Explore GLP-1 receptor therapy and its role in cardiometabolic health. Learn how it can benefit your well-being.

Abstract

Hello, I’m Dr. Alex Jimenez. In this comprehensive educational post, we will embark on a detailed journey into the modern management of type 2 diabetes and related cardiometabolic conditions. We’ll explore a paradigm shift away from a purely glucose-centric approach, focusing on the latest evidence-based research from leading investigators. I will highlight how two specific classes of medications, SGLT2 inhibitors and GLP-1 receptor agonists, offer significant cardiovascular and renal protection. This discussion is grounded in the landmark FDA-mandated cardiovascular outcomes trials (CVOTs), which have reshaped our clinical guidelines. We will delve into the physiological mechanisms behind these benefits, explaining how and why these drug classes work to reduce major adverse cardiovascular events (MACE), hospitalizations for heart failure, and the progression of kidney disease. You will also learn about clinical challenges such as “over-basalization” and how GLP-1 agonists offer a superior alternative to intensifying insulin therapy. Finally, I will detail how our multidisciplinary clinic, Injury Medical Clinic PA, integrates these advanced medical strategies with integrative chiropractic care, functional medicine, and comprehensive rehabilitation to provide holistic, patient-centered care for those managing complex metabolic conditions.

Our Collaborative and Integrative Practice

I am Dr. Alex Jimenez, and I hold credentials as a Doctor of Chiropractic (DC), Advanced Practice Registered Nurse (APRN), and a board-certified Family Nurse Practitioner (FNP-BC), along with certifications in Functional Medicine (CFMP, IFMCP), Advanced Technologies in Neurodiagnostics (ATN), and Clinical Chiropractic Spinal Trauma (CCST). In El Paso, Texas, our multidisciplinary clinic, Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic), operates under the esteemed medical direction of Dr. Maria Guadalupe Cardenas, MD. Dr. Cardenas is Board Certified in Internal Medicine (NPI #1164426749, Texas MD License #J2933) and brings over 40 years of invaluable experience to our team, serving as our Medical Director and Collaborative Physician.

This integrative setup, where a medical doctor provides direct oversight and collaborates with a chiropractor, is a cornerstone of modern evidence-based injury and metabolic care. Our model allows us to create a truly comprehensive treatment plan. Together, we combine:

• Internal medicine oversight (diagnostics, medication management, cardiovascular and renal risk management) by Dr. Cardenas.
• My expertise in integrative chiropractic care (spinal mechanics, neuromuscular re-education, autonomic regulation).
• Functional medicine and nutrition (root-cause evaluation of metabolic drivers, inflammation, and microbiome health).
• Personal injury rehabilitation (biomechanics, pain management, graded return to function).
• Behavioral coaching and lifestyle interventions (sleep, stress, movement).

This synergy ensures that our patients receive a holistic treatment plan that targets their condition from multiple angles—from advanced medical interventions to hands-on physical medicine and lifestyle coaching.

The New Paradigm: Beyond Glucose Control in Diabetes

For years, the primary goal in managing type 2 diabetes was simple: lower blood sugar. While controlling glucose remains important, we’ve learned that this approach is insufficient. People with diabetes face a dramatically elevated risk for atherosclerotic cardiovascular disease (ASCVD), which includes coronary heart disease, stroke, and peripheral arterial disease. In fact, ASCVD is the leading cause of death for this population.

Consider this staggering statistic: over 70% of individuals with diabetes over the age of 65 will likely die from heart disease or a stroke. The prognosis following a heart attack or stroke is significantly worse for people with diabetes, even when their blood sugar is well-controlled. This understanding has led to a major shift in our thinking. The new paradigm, now universally adopted by leading health organizations like the American College of Cardiology (ACC), American Heart Association (AHA), American Diabetes Association (ADA), and Kidney Disease: Improving Global Outcomes (KDIGO), is to focus on comprehensive risk factor reduction.

Foundational Principles of Modern Diabetes Care

• Comprehensive Risk Management: Our efforts are now directed at managing a constellation of risk factors concurrently. This includes blood pressure control, lipid management, glucose control, weight management, physical activity, and smoking cessation.
• Prioritizing Cardiorenal Protection: For patients with established ASCVD, heart failure, chronic kidney disease (CKD), or those at high risk, we no longer start with just any glucose-lowering medication. The guidelines now point us directly toward two specific classes of drugs with proven cardiovascular benefits: SGLT2 inhibitors and GLP-1 receptor agonists.

This shift is a direct result of groundbreaking research that I will discuss next.

The Turning Point: FDA Mandates and Cardiovascular Outcomes Trials (CVOTs)

How did we arrive at this new, more effective approach? The story begins in 2008 when the U.S. Food and Drug Administration (FDA) issued a mandatory guidance for all new antidiabetic agents. The FDA required pharmaceutical companies to conduct long-term, large-scale cardiovascular outcomes trials (CVOTs).

The primary goal of these trials was to prove that new diabetes drugs did not increase the risk of major adverse cardiovascular events (MACE). This composite measure typically includes cardiovascular death, non-fatal heart attack, and non-fatal stroke. What happened next surprised everyone. As data from these robust, placebo-controlled trials began to be published, we discovered that some of these new drugs didn’t just meet safety requirements—they were actively conferring cardiovascular and renal benefits.

The first breakthrough came in 2015 with the EMPA-REG OUTCOME trial for empagliflozin (Jardiance), an SGLT2 inhibitor. It showed a significant reduction in MACE and cardiovascular death (Zinman et al., 2015). This was followed in 2016 by the LEADER trial for liraglutide (Victoza), a GLP-1 receptor agonist, which also demonstrated clear cardiovascular protection (Marso et al., 2016). These surprising results fundamentally changed our treatment guidelines and ushered in the era of cardiorenal metabolic medicine.

A Deep Dive into SGLT2 Inhibitors: Mechanisms and Benefits

Let’s unpack the first of these game-changing drug classes: the Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors. This class includes drugs like empagliflozin (Jardiance), canagliflozin (Invokana), dapagliflozin (Farxiga), and ertugliflozin (Steglatro).

Landmark CVOTs for SGLT2 Inhibitors

The major trials revealed consistent and powerful benefits across the class, particularly in reducing hospitalization for heart failure.

• EMPA-REG OUTCOME (Jardiance): Showed significant reductions in MACE, CV death, and hospitalization for heart failure (Zinman et al., 2015).
• CANVAS Program (Invokana): Demonstrated reductions in MACE and hospitalization for heart failure (Neal et al., 2017).
• DECLARE-TIMI 58 (Farxiga): Showed a very strong reduction in heart failure hospitalizations.
• VERTIS-CV (Steglatro): Also achieved a significant reduction in hospitalization for heart failure, with a 30% relative risk reduction.

How Do SGLT2 Inhibitors Work? Unraveling the Mechanisms

The benefits of SGLT2 inhibitors extend far beyond simple glucose lowering. They induce a unique set of physiological changes that protect the heart and kidneys.

• Hemodynamic Effects:

• • Blood Pressure Reduction: They cause a modest but clinically meaningful drop in systolic blood pressure (around 5 mmHg) by promoting natriuresis (excretion of sodium) and acting as a gentle osmotic diuretic.
  • Reduced Glomerular Pressure: In the kidney’s filtering units (the nephrons), these drugs reduce pressure within the glomeruli. This is a key theorized mechanism underlying their profound nephroprotective effects, which slow the progression of diabetic kidney disease.

• Metabolic and Cellular Effects:

• • Weight Loss: They lead to a modest weight loss of around 5-7 pounds by causing the excretion of glucose (and its calories) in the urine.
  • Improved Myocardial Fuel Efficiency: The heart muscle functions more efficiently when it uses ketones as a fuel source. SGLT2 inhibitors promote a state of mild, beneficial ketosis, providing the heart with this preferred fuel.
  • Reduced Inflammation and Oxidative Stress: They have been shown to lower systemic markers of inflammation and oxidative stress, which are key drivers of atherosclerosis and organ damage.
  • Stabilized Arterial Plaque: They help improve endothelial function and may contribute to the stabilization of atherosclerotic plaques, making them less likely to rupture.

SGLT2 Inhibitors and Heart Failure: A Major Breakthrough

The benefits for heart failure are so significant that trials were designed to investigate this effect even in patients without diabetes.

• DAPA-HF and EMPEROR-Reduced Trials: In patients with heart failure with reduced ejection fraction (HFrEF), dapagliflozin and empagliflozin showed a 21-26% relative risk reduction in cardiovascular death and hospitalization for heart failure (McMurray et al., 2019).
• EMPEROR-Preserved Trial: This was the first trial to show a meaningful benefit in heart failure with preserved ejection fraction (HFpEF), a type common in people with obesity and diabetes. Empagliflozin reduced the risk of CV death or hospitalization for heart failure by 21% (Anker et al., 2021).

SGLT2 Inhibitors and Kidney Protection

The renal trials have been equally impressive, showing powerful nephroprotective effects.

• DAPA-CKD (dapagliflozin): Stopped early due to overwhelming efficacy, demonstrating a 47% relative risk reduction in nephropathy progression.
• EMPA-KIDNEY (empagliflozin): Demonstrated a 39% relative risk reduction in the progression of kidney disease (The EMPA-KIDNEY Collaborative Group, 2022).
• CANVAS (canagliflozin): Showed a 40% relative risk reduction in nephropathy (Neal et al., 2017).

The Challenge of Uncontrolled Diabetes: Over-Basalization and a Smarter Solution

Let’s consider a typical patient scenario. We’ll call him Tony, a 62-year-old male with type 2 diabetes, high cholesterol, hypertension, and early signs of kidney stress. His A1C is high at 8.2% despite taking metformin, an SGLT2 inhibitor, and a high dose of basal insulin (65 units daily). His fasting blood sugar is okay, but his post-meal numbers are consistently high.

Tony’s case perfectly illustrates a critical issue we call over-basalization.

Understanding “Over-Basalization”: When More Insulin Isn’t Better

Over-basalization occurs when increasing basal insulin doses yields diminishing returns and introduces risks. Pharmacokinetic studies have shown that at doses greater than 0.5 units per kilogram of body weight per day, the glucose-lowering effect of basal insulin becomes modest. Any further dose increases often lead to more side effects than benefits.

We identify over-basalization through a few key indicators:

• High Insulin Dose: The patient is taking more than 5 units/kg/day of basal insulin.
• Elevated Post-Meal Glucose: Blood sugars after meals consistently exceed 180 mg/dL.
• A1C Not at Goal: The A1C remains high despite fasting glucose levels being near target.
• Large Bedtime-to-Morning Differential: A drop in blood sugar from bedtime to morning greater than 50 mg/dL may suggest unrecognized nocturnal hypoglycemia.

Tony, at 100 kg (220 lbs), is on 65 units of insulin—well over the 50-unit threshold. He is a textbook example. The traditional next step might have been adding mealtime (prandial) insulin, but this increases complexity, weight gain, and hypoglycemia risk. Modern guidelines offer a better path.

A Deep Dive into GLP-1 Receptor Agonists: The Smarter Next Step

The 2024 ADA guidelines strongly recommend considering a GLP-1 receptor agonist before initiating prandial insulin for most patients (American Diabetes Association, 2024).

The Incretin Effect: The Science Behind GLP-1 Agonists

The concept is elegantly simple: oral glucose lowers blood sugar more effectively than intravenous glucose because it triggers gut hormones that amplify insulin secretion. This is the incretin effect. The key hormones are GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). In type 2 diabetes, this effect is blunted (Nauck & Meier, 2018). GLP-1 receptor agonists are medications that mimic or augment native GLP-1 to restore this crucial signaling pathway.

How GLP-1 Agonists Work

GLP-1 agonists have a sophisticated, glucose-dependent mechanism of action:

1. Enhances Insulin Secretion: They stimulate the pancreas to release insulin, but only when blood glucose is high, drastically reducing hypoglycemia risk.
2. Suppresses Glucagon: They inhibit the release of glucagon, a hormone that tells the liver to produce sugar, which is particularly effective at controlling post-meal glucose spikes (Drucker, 2018).
3. Slows Gastric Emptying: They slow the rate at which food leaves the stomach, preventing rapid glucose absorption and promoting fullness.
4. Promotes Satiety: They act on the brain to reduce appetite and increase feelings of fullness, thereby reducing calorie intake and promoting weight loss.

For a patient like Tony, adding a GLP-1 agonist is far more advantageous than adding prandial insulin. It targets his post-meal high blood sugar while also helping him lose weight with a low risk of hypoglycemia.

Landmark CVOTs for GLP-1 Agonists

Like SGLT2 inhibitors, GLP-1 agonists have demonstrated robust cardiorenal benefits in major trials.

• LEADER (Liraglutide): One of the first to show a reduction in MACE in high-risk patients (Marso et al., 2016).
• SUSTAIN-6 (Semaglutide): Showed significant MACE risk reduction in patients with established cardiovascular disease (Marso et al., 2016).
• REWIND (Dulaglutide): Uniquely showed MACE reduction in a broader population, supporting its use for primary prevention (Gerstein et al., 2019).
• FLOW (Semaglutide): Stopped early for overwhelmingly positive results, demonstrating a significant reduction in the progression of kidney disease and cardiovascular death in patients with CKD and type 2 diabetes (Mann et al., 2024).
• Tirzepatide (Mounjaro/Zepbound): A newer dual-agonist acting on both GLP-1 and GIP receptors, has shown even more powerful effects on A1C and weight loss (Frías et al., 2021). Its CVOT is ongoing, but initial data is extremely promising.

---

The Silent Threat: Hyperhomocysteinemia and its Impact on Your Health- Video

---

Integrating Chiropractic and Functional Medicine with Advanced Medical Care

At our clinic, we see the person, not just the disease. A patient with diabetes and heart disease also has a musculoskeletal system, a lifestyle, and a unique biochemistry. This is where our integrative model shines.

Let’s return to our case study, Loretta, a 72-year-old with a 15-year history of diabetes, coronary artery disease with stents, a high A1C of 8.1%, and declining kidney function.

1. Medical Management (Dr. Cardenas): Following the ADA guidelines, the clear next step is to add an SGLT2 inhibitor. This single addition would be expected to lower her A1C by about 1%, provide powerful heart and kidney protection, and help with modest weight loss. To simplify her regimen, we would recommend a combination pill containing an SGLT2 inhibitor and her existing metformin.
2. Chiropractic and Rehabilitative Care (Dr. Jimenez):

• • Structural Integrity: Chronic conditions like diabetes affect the entire body. I would perform a thorough biomechanical assessment to identify any joint restrictions or nerve impingement that may be limiting her mobility. Gentle chiropractic adjustments can improve joint function, reduce pain, and enhance nervous system communication, which is vital for overall health regulation.
  • Functional Movement: We would design a personalized, closely monitored rehabilitation program to improve her strength, balance, and cardiovascular endurance safely. Improving her mobility is not just about physical fitness; it’s about empowering her to live a more active life, which directly benefits her blood sugar control and heart health.

• Functional Medicine and Lifestyle Coaching:

• • Advanced Nutritional Support: We would create a personalized, anti-inflammatory, nutrient-dense eating plan that supports cardiovascular health and blood sugar stability. This goes beyond basic advice to address her unique metabolic needs.
  • Patient Education: We spend time educating Loretta on her new medication. We’d advise her to take it in the morning to manage the diuretic effect, stress the importance of hydration, and discuss hygiene to prevent the main side effect of genital mycotic infections.

Managing Side Effects and Special Considerations

When starting a GLP-1 agonist, we “start low and go slow” to minimize gastrointestinal side effects like nausea. We also provide robust education on:

• Hydration: Crucial to prevent dehydration-related acute kidney injury (AKI).
• Thyroid Safety: We avoid GLP-1s in patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
• Anesthesia Precautions: Due to delayed gastric emptying, we advise pausing therapy 1-2 weeks before scheduled procedures requiring sedation, in coordination with the anesthesiology team (Anesthesia Patient Safety Foundation, 2023).

Clinical Observations from My Practice

From my clinic and coaching platforms, I’ve observed several key patterns:

• Patients on GLP-1 agents report a marked decrease in “food noise”. Pairing this with structured, protein-first meal plans sustains weight loss while minimizing GI issues.
• Reducing chronic low back pain with integrative chiropractic interventions directly improves patients’ ability to exercise, thereby improving their glycemic control. Activity is the bridge between pharmacology and physiology.
• Sleep optimization enhances insulin sensitivity and reduces cravings. We often see lower morning glucose levels with improved sleep quality.

By combining Dr. Cardenas’s medical expertise in prescribing the right evidence-based medication with my focus on structural health, functional movement, and lifestyle optimization, we provide patients like Loretta and Tony with a truly comprehensive care plan that addresses the root causes and effects of their condition, improving not just their lab numbers, but their quality of life.

References

• American Diabetes Association. (2023). 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes—2023. Diabetes Care, 46(Supplement_1), S140–S157.
• American Diabetes Association. (2024). 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes—2024. Diabetes Care, 47(Supplement 1), S158–S178.
• Anesthesia Patient Safety Foundation. (2023). APSF guidance on GLP-1 receptor agonists and anesthesia risk.
• Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., … & Packer, M. (2021). Empagliflozin in heart failure with a preserved ejection fraction. New England Journal of Medicine, 385(16), 1451-1461.
• Drucker, D. J. (2018). Mechanisms of action and therapeutic applications of GLP-1. Cell Metabolism.
• The EMPA-KIDNEY Collaborative Group. (2022). Empagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 388(2), 117-127.
• Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503–515.
• Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., & on behalf of the REWIND Investigators. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomized placebo-controlled trial. The Lancet, 394(10193), 121–130.
• Mann, J. F. E., et al. (2024). FLOW: Semaglutide and kidney outcomes in type 2 diabetes. New England Journal of Medicine.
• Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., Vilsbøll, T., & on behalf of the SUSTAIN-6 Investigators. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1834–1844.
• Marso, S. P., et al. (2016). LEADER: Liraglutide and reduced cardiovascular events. New England Journal of Medicine.
• McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., … & DeMets, D. L. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381(21), 1995-2008.
• Nauck, M. A., & Meier, J. J. (2018). Incretins and their relevance to type 2 diabetes. Nature Reviews Endocrinology.
• Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., … & Matthews, D. R. (2017). Canagliflozin and cardiovascular and renal events in type 2 diabetes. New England Journal of Medicine, 377(7), 644-657.
• Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., … & Inzucchi, S. E. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine, 373(22), 2117-2128.

SEO Tags: SGLT2 inhibitors, GLP-1 receptor agonists, diabetes management, cardiovascular disease, chronic kidney disease, integrative chiropractic care, functional medicine, Dr. Alex Jimenez, Dr. Maria Cardenas, El Paso TX, heart failure, ASCVD, cardiorenal protection, over-basalization, empagliflozin, semaglutide, tirzepatide, diabetes risk reduction, MACE, cardiovascular outcomes trials, A1C, weight loss, postprandial hyperglycemia, ADA Guidelines, incretin effect